News
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
13d
Investor's Business Daily on MSNCVS Stock Surges On Huge Q1 Beat Amid GLP-1 Deal With Novo NordiskCVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to ...
On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...
1d
MedPage Today on MSNCVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' BankruptcyPeople prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
2d
Axios on MSNExclusive: Oikos adds protein shakes geared to GLP-1 usersHigh-protein yogurt brand Oikos is expanding beyond the dairy aisle with protein shakes geared to GLP-1 users, Danone North ...
But CVS Health spokesman David Whitrap said most ... Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the ...
new relationship with Novo Nordisk is claiming it as the exclusive partner for its formulary for the GLP-1s. That's for weight loss. Um, there's also some other news around CVS with it ...
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
The Associated Press on MSN13d
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS HealthWegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results